Biovitrum closes Swedish Orphan acquisition
This article was originally published in Scrip
Executive Summary
Biovitrum has completed its acquisition of the speciality company Swedish Orphan by paying around SEK1.9 billion ($271 million) in cash and up to 58.3 million shares in Biovitrum.